General Western Blot Reagents
Abcam Methyl tetracosanoate, Fatty acid methyl ester, 100MG
MW 382.7 Da, Purity >99%. Fatty acid methyl ester. Antidiabetic activity. Active in vitro. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Methyl 3-hydro x ytetradecanoate, 3-Hydro x y fatty acid methyl ester, 25MG
MW 258.4 Da, Purity >98%. 3-Hydroxy fatty acid methyl ester. Internal standard. See similar products
The product is subject to the following: Abcam Restricted Use Statement
Abcam Atpenin A5, ubiquinone-binding site mitochondrial comple x II inhibitor, 1MG
MW 366.2 Da, Purity >95%. Highly selective, potent ubiquinone-binding site mitochondrial complex II inhibitor (IC₅₀ values are 12 and 3.7 nM for nematode and mammalian mitochondria respectively). Stimulates mitochondrial KATP channels. Shows anti-ischemic and cardioprotective effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Methyl 3-hydro x yhe x anoate, 3-Hydro x y fatty acid methyl ester, 25MG
MW 146.18 Da, Purity >98%. 3-Hydroxy fatty acid methyl ester. For use as standard in methanolysis assay and in biological systems. See similar products
The product is subject to the following: Abcam Restricted Use Statement
Abcam Coprostanol, Cholesterol derivative, 25MG
MW 388.7 Da, Purity >98%. Cholesterol (ab142501) derivative. Forms from bacterial biohydrogenation of cholesterol. Biomarker for vertebrate intestinal microbe populations in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Reduced Cytochrome C.
Reduced Cytochrome C.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Deltamethrin, protein phosphatase 2B inhibitor, 50MG
MW 505.2 Da, Purity >98%. Potent protein phosphatase 2B inhibitor (IC₅₀ = 0.03 nM). Induces neurotoxicity by slowing the opening and closing of Na+ channels. Active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ML-9, protein kinase inhibitor, 10MG
MW 361.3 Da, Purity >98%. Broad spectrum ATP-competitive protein kinase inhibitor (Ki values are 32, 4, and 54 μM for PKA, MLCK, and PKC respectively). Ca²+ channel blocker. Shows vasorelaxant effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Asta x anthin, Antio x idant agent, 25MG
MW 596.8 Da, Purity >97%. Potent antioxidant agent. PPARα agonist and PPARγ antagonist. Free radical scavenger. Reduces oxidative stress. Induces apoptosis. Inhibits NF-κB. Shows anti-inflammatory, antihypertensive, cardioprotective, neuroprotective and antitumor effects in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Asta x anthin, Antio x idant agent, 5MG
MW 596.8 Da, Purity >97%. Potent antioxidant agent. PPARα agonist and PPARγ antagonist. Free radical scavenger. Reduces oxidative stress. Induces apoptosis. Inhibits NF-κB. Shows anti-inflammatory, antihypertensive, cardioprotective, neuroprotective and antitumor effects in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam N-Acetylphytosphingosine (NAPS), Sphingolipid ceramide derivative, 5MG
MW 359.5 Da, Purity >98%. Sphingolipid ceramide derivative. Induces caspase-dependent apoptosis. Anticancer agent. Potential NF-κB and JAK/STAT signaling inhibitor. Active in vitro and potentially in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Bisindolylmaleimide x I hydrochloride, PKC inhibitor, 5MG
MW 489 Da, Purity >98%. Selective, cell-permeable protein kinase C (PKC) inhibitor that displays 10-fold greater selectivity for PKCα (IC₅₀ = 9 nM) and 4-fold greater selectivity for PKCβI (IC₅₀ = 28 nM) over Ca²+-independent PKCε (IC₅₀ = 108 nM). Enhances cardiac contractility and protection from heart failure. Prevents T-cell activation and proliferation (IC₅₀s ranging from 30-150 nM) associated with chronic inflammatory responses in vivo. Also inhibits GRK2, GRK5, and GRK6 (IC₅₀ values are 29, 3.6, and 16 μM, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam ML-9, protein kinase inhibitor, 250MG
MW 361.3 Da, Purity >98%. Broad spectrum ATP-competitive protein kinase inhibitor (Ki values are 32, 4, and 54 μM for PKA, MLCK, and PKC respectively). Ca²+ channel blocker. Shows vasorelaxant effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Pyocyanin, Catalase inhibitor, 5MG
MW 210.23 Da, Purity >98%. Catalase inhibitor. Aryl hydrocarbon receptor activator (Ki = 5.4 μM). Reduces gene expression of catalase. Promotes extracellular DNA release. Generates ROS. Induces apoptosis in neutrophils in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Spermidine hydrochloride, nNOS inhibitor, 100MG
MW 254.6 Da. Endogenous polyamine, that binds to the polyamine modulatory site of the NMDA receptor. Inhibits neuronal nitric oxide synthase (nNOS). Binds and precipitates DNA; may be used for purification of DNA binding proteins.
The product is subject to the following: Abcam Restricted Use Statement